Global Anti-Obesity Prescription Drugs Market Research Report, Competitive, Technology and Forecast Analysis 2026-2033

According to DIResearch＇s in-depth investigation and research, the global Anti-Obesity Prescription Drugs market size will reach Million USD in 2026 and is projected to reach Million USD by 2033, with a CAGR of % (2026-2033). Notably, the China Anti-Obesity Prescription Drugs market has changed rapidly in the past few years. By 2026, China＇s market size is expected to be Million USD, representing approximately % of the global market share.

Research Summary

Anti-obesity prescription drugs are medications that are prescribed by doctors to people who are obese or overweight in order to help them lose weight by suppressing the appetite or reducing the absorption of fat in the body. These drugs work by changing the way the body processes food and nutrients, and may also cause changes in metabolism and energy levels. Some common anti-obesity prescription drugs include phentermine, liraglutide, orlistat, and Belviq. These drugs are typically used in combination with diet and exercise to achieve maximum weight loss results.

The major global suppliers of Anti-Obesity Prescription Drugs include F Hoffmann La Roche Ltd, Orexigen Therapeutics, Novo Nordisk A/s, Arena Pharmaceuticals, Glaxosmithkline, Vivus, Boehringer Ingelheim, Alizyme, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.

This report studies the market size, price trends and future development prospects of Anti-Obesity Prescription Drugs. Focus on analysing the market share, product portfolio, prices, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Anti-Obesity Prescription Drugs market. The report data covers historical data from 2021 to 2025, based year in 2026 and forecast data from 2027 to 2033.

The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Anti-Obesity Prescription Drugs market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Anti-Obesity Prescription Drugs industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Suppliers of Anti-Obesity Prescription Drugs Include:

F Hoffmann La Roche Ltd

Orexigen Therapeutics

Novo Nordisk A/s

Arena Pharmaceuticals

Glaxosmithkline

Vivus

Boehringer Ingelheim

Alizyme

Anti-Obesity Prescription Drugs Product Segment Include:

Wegovy

Saxenda

Zepbound

Xenical

Others

Anti-Obesity Prescription Drugs Product Application Include:

Hospitals Pharmacies

Retail Pharmacies

E-commerce

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend

Chapter 2: Global Anti-Obesity Prescription Drugs Industry PESTEL Analysis

Chapter 3: Global Anti-Obesity Prescription Drugs Industry Porter's Five Forces Analysis

Chapter 4: Global Anti-Obesity Prescription Drugs Major Regional Market Size (Revenue) and Forecast Analysis

Chapter 5: Global Anti-Obesity Prescription Drugs Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 6: Global Anti-Obesity Prescription Drugs Revenue and Forecast Analysis by Product Type

Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 8: Industrial Chain Analysis, Anti-Obesity Prescription Drugs Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis

Chapter 9: Research Findings and Conclusion

Chapter 10: Methodology and Data Sources

Table 1： Anti-Obesity Prescription Drugs Industry Development Status

Table 2： Anti-Obesity Prescription Drugs Industry Development Trends

Table 3： Global Anti-Obesity Prescription Drugs Revenue and Growth Rate (CAGR) by Country: 2025 VS 2026 VS 2033 (US$ Million)

Table 4： Global Anti-Obesity Prescription Drugs Revenue by Country (2021-2026) & (US$ Million)

Table 5： Global Anti-Obesity Prescription Drugs Revenue Market Share by Country (2021-2026)

Table 6： Global Anti-Obesity Prescription Drugs Revenue Forecast by Country (2027-2033) & (US$ Million)

Table 7： Global Anti-Obesity Prescription Drugs Revenue Market Share Forecast by Country (2027-2033)

Table 8： Global Anti-Obesity Prescription Drugs Market Revenue by Key Suppliers (2021-2026) & (US$ Million)

Table 9： Global Anti-Obesity Prescription Drugs Revenue Market Share by Key Suppliers (2021-2026)

Table 10： Global Key Suppliers Headquarter and Key Area Sales

Table 11： Market Mergers & Acquisitions, Expansion

Table 12： Global Anti-Obesity Prescription Drugs Market Size and Growth Rate (CAGR) Analysis by Type: 2025 VS 2026 VS 2033 (US$ Million)

Table 13： Global Anti-Obesity Prescription Drugs Revenue Analysis by Type (2021-2026) & (US$ Million)

Table 14： Global Anti-Obesity Prescription Drugs Revenue Forecast Analysis by Type (2027-2033) & (US$ Million)

Table 15： F Hoffmann La Roche Ltd Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

Table 16： F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Portfolio

Table 17： F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Revenue (US$ Million), Gross Margin and Market Share (2021-2026)

Table 18： Orexigen Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

Table 19： Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Portfolio

Table 20： Orexigen Therapeutics Anti-Obesity Prescription Drugs Revenue (US$ Million), Gross Margin and Market Share (2021-2026)

Table 21： Novo Nordisk A/s Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

Table 22： Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Portfolio

Table 23： Novo Nordisk A/s Anti-Obesity Prescription Drugs Revenue (US$ Million), Gross Margin and Market Share (2021-2026)

Table 24： Arena Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

Table 25： Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Portfolio

Table 26： Arena Pharmaceuticals Anti-Obesity Prescription Drugs Revenue (US$ Million), Gross Margin and Market Share (2021-2026)

Table 27： Glaxosmithkline Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

Table 28： Glaxosmithkline Anti-Obesity Prescription Drugs Product Portfolio

Table 29： Glaxosmithkline Anti-Obesity Prescription Drugs Revenue (US$ Million), Gross Margin and Market Share (2021-2026)

Table 30： Vivus Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

Table 31： Vivus Anti-Obesity Prescription Drugs Product Portfolio

Table 32： Vivus Anti-Obesity Prescription Drugs Revenue (US$ Million), Gross Margin and Market Share (2021-2026)

Table 33： Boehringer Ingelheim Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

Table 34： Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Portfolio

Table 35： Boehringer Ingelheim Anti-Obesity Prescription Drugs Revenue (US$ Million), Gross Margin and Market Share (2021-2026)

Table 36： Alizyme Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

Table 37： Alizyme Anti-Obesity Prescription Drugs Product Portfolio

Table 38： Alizyme Anti-Obesity Prescription Drugs Revenue (US$ Million), Gross Margin and Market Share (2021-2026)

Table 39： Global Anti-Obesity Prescription Drugs Market Size and Growth Rate (CAGR) by Application: 2025 VS 2026 VS 2033 & (US$ Million)

Table 40： Global Anti-Obesity Prescription Drugs Revenue Analysis by Application (2021-2026) & (US$ Million)

Table 41： Global Anti-Obesity Prescription Drugs Revenue Forecast Analysis by Application (2027-2033) & (US$ Million)

Table 42： Anti-Obesity Prescription Drugs Typical Customer List

Table 43： Anti-Obesity Prescription Drugs Distributors List

Figure 1： Anti-Obesity Prescription Drugs Product Pictures

Figure 2： Wegovy Picture Scope

Figure 3： Saxenda Picture Scope

Figure 4： Zepbound Picture Scope

Figure 5： Xenical Picture Scope

Figure 6： Others Picture Scope

Figure 7： Hospitals Pharmacies Picture Scope

Figure 8： Retail Pharmacies Picture Scope

Figure 9： E-commerce Picture Scope

Figure 10： Global Anti-Obesity Prescription Drugs Market Size Analysis：2025 VS 2026 VS 2033 (US$ Million)

Figure 11： Global Anti-Obesity Prescription Drugs Market Revenue and Growth Rate Analysis: (2021-2033) & (US$ Million)

Figure 12： Global Anti-Obesity Prescription Drugs Revenue Market Share by Country in 2025

Figure 13： United States Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2021-2033) & (US$ Million)

Figure 14： Germany Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2021-2033) & (US$ Million)

Figure 15： Japan Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2021-2033) & (US$ Million)

Figure 16： China Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2021-2033) & (US$ Million)

Figure 17： France Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2021-2033) & (US$ Million)

Figure 18： U.K. Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2021-2033) & (US$ Million)

Figure 19： South Korea Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2021-2033) & (US$ Million)

Figure 20： Canada Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2021-2033) & (US$ Million)

Figure 21： Italy Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2021-2033) & (US$ Million)

Figure 22： Russia Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2021-2033) & (US$ Million)

Figure 23： Mexico Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2021-2033) & (US$ Million)

Figure 24： Brazil Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2021-2033) & (US$ Million)

Figure 25： India Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2021-2033) & (US$ Million)

Figure 26： Vietnam Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2021-2033) & (US$ Million)

Figure 27： Thailand Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2021-2033) & (US$ Million)

Figure 28： South Africa Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2021-2033) & (US$ Million)

Figure 29： Global Anti-Obesity Prescription Drugs Revenue Market Share by Key Suppliers in 2025

Figure 30： Global Anti-Obesity Prescription Drugs Industry Competition Landscape

Figure 31： Global Anti-Obesity Prescription Drugs Market Size by Type (2021-2033) (US$ Million)

Figure 32： Global Anti-Obesity Prescription Drugs Market Share by Type: 2026 & 2033

Figure 33： Anti-Obesity Prescription Drugs Industry Chain Analysis

Figure 34： Global Anti-Obesity Prescription Drugs Revenue Market Share by Application (2021-2033)

Figure 35： Key Interview Objectives

Figure 36： Bottom-Up and Top-Down Research Methods